The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception.
The novel CCK antagonist L364,718 was tested on caerulein- and morphine-induced antinociception in rat using the paw pressure test. Caerulein-induced antinociception (ED50 = 30 micrograms/kg) was significantly inhibited by L354,718 (200 micrograms/kg i.p.) which on its own did not affect paw pressure threshold. In contrast, morphine-induced antinociception was significantly potentiated by L364,718. Since L364,718 is highly selective for 'peripheral' receptors which are found in tissue such as pancreas and gallbladder and a few discrete areas of brain, this receptor is likely to be implicated in the antinociceptive effect of caerulein.
Rattray
M
M
Department of Biochemistry, Charing Cross and Westminster Medical School, London, U.K.
Jordan
C C
CC
De Belleroche
J
J
D000700:Analgesics; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002108:Ceruletide / Q000037:antagonists & inhibitors*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D004347:Drug Interactions; D005260:Female; D009020:Morphine / Q000494:pharmacology*; D010146:Pain / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains; D011930:Reaction Time / Q000187:drug effects; D012684:Sensory Thresholds / Q000187:drug effects
D000700:Analgesics; D001570:Benzodiazepinones; D009020:Morphine; D002108:Ceruletide; D002766:Cholecystokinin; D020109:Devazepide